Company intelligence / Profile preview

Guangzhou Ruibes Pharmaceutical

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangzhou Ruibes Pharmaceutical is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative small molecule drugs for metabolic diseases. The company's primary focus is on treating Type 2 diabetes and related metabolic syndromes through novel mechanisms such as GPR119 agonism. Ruibes maintains a robust R&D pipeline that includes both proprietary new chemical entities and improved formulations of existing therapies. Headquartered in Guangzhou, the company leverages local clinical resources to advance its candidates through various stages of clinical development in the Chinese market.

Therapeutic areas: EndocrinologyCardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Guangzhou Ruibes Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Ruibes Pharmaceutical.

Explore the full profile